[go: up one dir, main page]

ECSP11011546A - Composición farmacéutica para la anticoncepción de emergencia - Google Patents

Composición farmacéutica para la anticoncepción de emergencia

Info

Publication number
ECSP11011546A
ECSP11011546A ECSP11011546A ECSP11011546A EC SP11011546 A ECSP11011546 A EC SP11011546A EC SP11011546 A ECSP11011546 A EC SP11011546A EC SP11011546 A ECSP11011546 A EC SP11011546A
Authority
EC
Ecuador
Prior art keywords
concept
pharmaceutical composition
emergency anti
pharmaceutical compositions
emergency
Prior art date
Application number
Other languages
English (en)
Inventor
Rolf Schuermann
Sascha General
Bernhard Lindenthal
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of ECSP11011546A publication Critical patent/ECSP11011546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas para la anticoncepción de emergencia, al uso de levonorgestrel en combinación con inhibidores de Cox para la preparación de composiciones farmacéuticas para la finalidad mencionada, así como a un procedimiento para la preparación de estas composiciones farmacéuticas.
ECSP11011546 2009-06-23 2011-12-22 Composición farmacéutica para la anticoncepción de emergencia ECSP11011546A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009030607 2009-06-23

Publications (1)

Publication Number Publication Date
ECSP11011546A true ECSP11011546A (es) 2012-01-31

Family

ID=42830690

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP11011546 ECSP11011546A (es) 2009-06-23 2011-12-22 Composición farmacéutica para la anticoncepción de emergencia

Country Status (29)

Country Link
US (2) US8921345B2 (es)
EP (2) EP3178476A1 (es)
JP (2) JP5801801B2 (es)
KR (1) KR20120044307A (es)
CN (1) CN102458386B (es)
AR (1) AR077199A1 (es)
AU (1) AU2010265180B2 (es)
BR (1) BRPI1011815A2 (es)
CA (1) CA2766197C (es)
CL (1) CL2011003291A1 (es)
CO (1) CO6480948A2 (es)
CR (1) CR20110699A (es)
CU (1) CU20110239A7 (es)
DO (1) DOP2011000402A (es)
EA (1) EA023780B1 (es)
EC (1) ECSP11011546A (es)
ES (1) ES2625950T3 (es)
IL (2) IL216668A (es)
MA (1) MA33373B1 (es)
MX (1) MX2011013959A (es)
MY (1) MY158476A (es)
NZ (1) NZ597239A (es)
PE (1) PE20120860A1 (es)
SG (1) SG177284A1 (es)
TN (1) TN2011000656A1 (es)
TW (1) TWI466673B (es)
UA (1) UA108741C2 (es)
UY (1) UY32728A (es)
WO (1) WO2010149273A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890025A (zh) * 2009-05-20 2010-11-24 北京紫竹药业有限公司 孕二烯酮在制备紧急避孕药物中的应用
EP3178476A1 (de) 2009-06-23 2017-06-14 Bayer Intellectual Property GmbH Pharmazeutische zusammensetzung und behandlungsverfahren zur notfallempfängnisverhütung
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
BR112015011212A2 (pt) * 2012-11-22 2017-07-11 Bayer Pharma AG uso e regime de aplicação de uma composição farmacêutica contendo levonorgestrel e um inibidor de cox para a contracepção necessária ("on demand")
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2015016121A (es) 2013-05-23 2016-03-31 Bayer Pharma AG Composicion farmaceutica, su uso y regimen de administracion para contracepcion a demanda.
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
KR101650778B1 (ko) 2014-10-17 2016-08-25 충북대학교 산학협력단 폴로유사인산화효소-1의 폴로박스 도메인에 특이적으로 결합하는 펩타이드 유사체 및 이를 유효성분으로 포함하는 피임용 조성물
SMT202200102T1 (it) 2015-06-18 2022-05-12 Estetra Srl Unità di dosaggio orodispersibile contenente un componente di estetrolo
JP6813150B2 (ja) 2015-06-18 2021-01-13 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
DK3106148T3 (en) 2015-06-18 2018-05-07 Mithra Pharmaceuticals S A Orodispersible dosing unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN107383353A (zh) * 2017-08-31 2017-11-24 浙江道明光电科技有限公司 一种硅烷改性聚酯预聚物的制备方法
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US11376263B2 (en) * 2020-10-08 2022-07-05 Fortress Biotech, Inc. Cyproterone acetate compositions and uses thereof
WO2022225986A1 (en) * 2021-04-19 2022-10-27 Archer David Fitzgerald On demand female contraceptive
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031631A1 (en) 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US20050143360A1 (en) * 2001-02-02 2005-06-30 Joel Krasnow Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
HU227198B1 (en) * 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
US20040058975A1 (en) * 2002-06-26 2004-03-25 Schering Ag Method for fertility control
EP3178476A1 (de) 2009-06-23 2017-06-14 Bayer Intellectual Property GmbH Pharmazeutische zusammensetzung und behandlungsverfahren zur notfallempfängnisverhütung
BR112015011212A2 (pt) 2012-11-22 2017-07-11 Bayer Pharma AG uso e regime de aplicação de uma composição farmacêutica contendo levonorgestrel e um inibidor de cox para a contracepção necessária ("on demand")

Also Published As

Publication number Publication date
MX2011013959A (es) 2012-01-25
MY158476A (en) 2016-10-14
WO2010149273A1 (de) 2010-12-29
DOP2011000402A (es) 2012-01-15
IL216668A0 (en) 2012-02-29
JP2012530733A (ja) 2012-12-06
IL216668A (en) 2016-03-31
EP2445491B1 (de) 2017-03-08
TW201105330A (en) 2011-02-16
CN102458386A (zh) 2012-05-16
IL244293A0 (en) 2016-04-21
TWI466673B (zh) 2015-01-01
CU20110239A7 (es) 2012-04-15
US20120172343A1 (en) 2012-07-05
JP2015163646A (ja) 2015-09-10
JP5801801B2 (ja) 2015-10-28
MA33373B1 (fr) 2012-06-01
EA023780B1 (ru) 2016-07-29
CL2011003291A1 (es) 2012-07-27
HK1170686A1 (zh) 2013-03-08
CN102458386B (zh) 2016-04-06
EA201200029A1 (ru) 2012-07-30
KR20120044307A (ko) 2012-05-07
CR20110699A (es) 2012-03-12
CA2766197A1 (en) 2010-12-29
SG177284A1 (en) 2012-02-28
US20150105359A1 (en) 2015-04-16
NZ597239A (en) 2013-07-26
AU2010265180B2 (en) 2014-09-11
AU2010265180A1 (en) 2012-01-19
ES2625950T3 (es) 2017-07-21
BRPI1011815A2 (pt) 2016-03-29
PE20120860A1 (es) 2012-07-15
US8921345B2 (en) 2014-12-30
AR077199A1 (es) 2011-08-10
EP2445491A1 (de) 2012-05-02
EP3178476A1 (de) 2017-06-14
CA2766197C (en) 2017-07-25
US9907806B2 (en) 2018-03-06
UA108741C2 (uk) 2015-06-10
TN2011000656A1 (en) 2013-05-24
UY32728A (es) 2011-01-31
CO6480948A2 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
CU20110239A7 (es) Composición farmacéutica para la anticoncepción de emergencia
JOP20180102A1 (ar) مركب صيدلاني
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
UY33735A (es) Compuestos antivirales
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
GT201400111A (es) Triazolopiridinas sustituidas
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2012000258A1 (es) Proceso para la preparacion de composicion de aglomerante hidraulico asperjable que contiene como principales componentes agua, agregados, aglomerante hidraulico, acelerador de fraguado, aglomerante hidraulico asperjable; composicion; y uso
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BR112012009310A2 (pt) composto, e, composição farmacêutica
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
GT200600221A (es) Tigeciclina y metodos de preparacion
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO6980142A1 (es) Composición de catalizador que se propone para el uso con composiciones puzolánicas
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
ECSP10010200A (es) Derivados de pirazol como inhibidores de 5-lo
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
CR11755A (es) Dronedarona para la prevencion de la cardioversion
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.